Human glucagon-like-peptide-1 modulators and their use in...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S002600, C514S004300, C514S015800, C530S300000, C530S327000, C530S330000, C530S333000

Reexamination Certificate

active

07417028

ABSTRACT:
The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 5998375 (1999-12-01), Thøgersen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6548667 (2003-04-01), Park et al.
patent: 6737417 (2004-05-01), Jo et al.
patent: 2002/0019419 (2002-02-01), De Laszlo et al.
patent: 2003/0195157 (2003-10-01), Natarajan et al.
patent: 0 142 146 (1985-05-01), None
patent: 0 221 025 (1987-05-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/34332 (2000-06-01), None
patent: WO 03/033671 (2003-04-01), None
patent: WO 2004/094461 (2004-11-01), None
C.W. Thornber. Chem. Soc. Rev. (1979) 8(4), pp. 563-580.
U.S. Appl. No. 11/172,488, filed Jun. 30, 2005, Mathur et al.
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Atheron, E. et al., Chapter 1: “The Fluorenylmethoxycarbonyl Amino Protecting Group”, The Peptides: Analysis, Synthesis, Biology, vol. 9: Special Methods in Peptide Synthesis, Part C, Academic Press, Inc., publ., Udenfriend, S. et al., eds., pp. 1-38 (1987).
Barany, G. et al., Chapter 1: “Solid-Phase Peptide Synthesis”, The Peptides: Analysis, Synthesis, Biology, vol. 2: Special Methods in Peptide Synthesis, Part A, Academic Press, Inc., publ., Gross, E. et al., eds., pp. 1-284 (1979).
Biller, S.A. et al., “Isoprenoid (Phoshinlmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Burgess, K. et al., “Solid Phase Syntheses of Oligoureas”, J. Am. Chem. Soc., vol. 119, No. 7, pp. 1556-1564 (1997).
Byrne, M.M. et al., “Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia”, European Journal of Clinical Investigation, vol. 28, pp. 72-78 (1998).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demostration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, Journal of the American Chemical Society, vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, No. 1, pp. 11-20 (1999).
Davern, P. et al., “Chemical and Biological Reactivity of Sulfamidopenicillins”, J. Chem. Soc. Perkin Trans. 2, pp. 381-387 (1994).
Fehder, W.P. et al., “Development and Evaluation of a Chromatographic Procedure for Partial Purification of Substance P with Quantitation by an Enzyme Immunassay”, Clinical and Diagnostic Laboratory Immunology, vol. 5, No. 3, pp. 303-307 (1998).
Fehrentz, J.-A. et al., “An Efficient Synthesis of Optically Active α(t-Butoxycarbonylamino)-aldehydes from α-Amino Acids”, Synthesis, pp. 676-678 (1983).
Fingl, E. et al., Section I: “Introduction”, Chapter I: “General Principles”, The Pharmacological Basics of Therapeutics, 5thEd., Macmillan Publishing Co., Inc., publ., Goodman, L.S. et al., eds., pp. 1-46 (1975).
Flint, A. et al., “Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans”, J. Clin. Invest., vol. 101, No. 3, pp. 515-520 (1998).
Gennaro, A.R., ed., Remington's Pharmaceutical Sciences, 18thEd., Mack Publishing Company, publ., pp. xv-xvi (table of contents) (1990).
Gennaro, A.R., ed., Remington: Practice of the Science and Pharmacy, 19thEd., Mack Publishing Company, publ., pp. xv-xvi (table of contents) (1995).
Gennaro, A.R., ed., Reminton: Practice of the Science and Pharmacy, vol. II, 19thEd., Mack Publishing Company, publ., pp. vii-viii (table of contents) (1995).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16, No. 1, pp. 16-30 (1998).
Gluschankof, P. et al., “Enzymes processing somatostatin precursors: An Arg-Lys esteropeptidase from the rat brain cortex converting somatostain-28 into somatostatin-14”, Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6662-6666 (1984).
Gutzwiller, J.-P. et al., “Gluc

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Human glucagon-like-peptide-1 modulators and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human glucagon-like-peptide-1 modulators and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human glucagon-like-peptide-1 modulators and their use in... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3996847

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.